Treatment, Emotion, and Neuromodulation of Depression (TREND) Study
Launched by ERIKA FORBES · Jun 24, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The TREND Study is a clinical trial aimed at exploring a new treatment for depression. Researchers will use a technique called theta burst stimulation (TBS), which involves gentle pulses of magnetic energy to help improve mood and reduce symptoms of depression. Some participants in the study will also receive training to boost their positive feelings during this treatment. The trial is currently looking for people aged 65 to 94 who have been diagnosed with a depressive disorder.
To participate in the study, you must be currently experiencing symptoms of depression, but you cannot have a history of certain conditions like bipolar disorder or severe substance use. If you join the trial, you will receive TBS treatment and may also be involved in additional positive training sessions. It's important to note that some individuals, such as those with specific neurological disorders or certain medical conditions, may not be eligible to participate. If you think you might be interested, it's a great opportunity to potentially contribute to advancements in depression treatment while receiving care that could improve your well-being.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Current Diagnostic and Statistical Manual (DSM-5) Depressive Disorder
- Exclusion Criteria:
- • Bipolar disorder (lifetime)
- • Obsessive-compulsive disorder (lifetime)
- • History of psychosis
- • Daily use of nicotine
- • Past-month use of cocaine, amphetamines, Methyl enedioxy methamphetamine (MDMA), Phencyclidine (PCP), Ketamine, or gamma-hydroxybutyrate (GHB)
- • Past 6 month substance use disorder
- • Binge drinking (using NIAAA criteria) within the past week, alcohol use in the past 12 hours
- • Neurological disorders: Epilepsy, Parkinson's Disease, brain tumor, brain injury, stroke
- • History of head trauma with a loss of consciousness (e.g., concussion)
- • History of seizures
- • MRI contraindications: body shape/size too large to fit in scanner, claustrophobia, and ferromagnetic metal in the body
- • Pregnancy
- • Current use of Clozapine, Bupropion, or prescription stimulants
- • Current use of benzodiazepines or mood stabilizers
- • Body shape/size too large to fit in MRI scanner
- • Claustrophobia
- • Metal in the head or ferromagnetic metal in the rest of the body
- • Implanted medical devices
- • High-risk suicidality
About Erika Forbes
Erika Forbes is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and a collaborative approach to clinical development, her organization plays a pivotal role in facilitating trials that adhere to the highest ethical and regulatory standards. By leveraging her extensive expertise in clinical operations and stakeholder engagement, Erika Forbes aims to foster partnerships that drive scientific discovery and bring transformative treatments to market. Through meticulous planning and execution, her team is dedicated to enhancing the efficiency of clinical trials while prioritizing patient safety and data integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Erika E Forbes, Ph.D
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials